Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN.

Clin Cancer Res. 2010 Oct 1;16(19):4742-54. doi: 10.1158/1078-0432.CCR-10-0529. Epub 2010 Jul 20.

2.

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.

Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T.

Br J Cancer. 2011 Jan 4;104(1):91-100. doi: 10.1038/sj.bjc.6606007. Epub 2010 Dec 7.

3.

Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells.

Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, Ha K, Buckley KM, Balusu R, Coothankandaswamy V, Joshi A, Atadja P, Bhalla KN.

Mol Cancer Ther. 2010 Apr;9(4):942-52. doi: 10.1158/1535-7163.MCT-09-0988. Epub 2010 Apr 6.

4.

Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.

Sato A, Asano T, Isono M, Ito K, Asano T.

BMC Urol. 2014 Aug 30;14:71. doi: 10.1186/1471-2490-14-71.

5.

KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA.

Blood. 2012 Feb 9;119(6):1450-8. doi: 10.1182/blood-2011-04-346676. Epub 2011 Dec 5.

6.

Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K.

Clin Cancer Res. 2012 Nov 15;18(22):6227-38. doi: 10.1158/1078-0432.CCR-12-0873. Epub 2012 Aug 29.

7.

Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ.

Mol Cancer Ther. 2010 Jul;9(7):2026-36. doi: 10.1158/1535-7163.MCT-10-0238. Epub 2010 Jul 6.

8.

Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN.

Cancer Biol Ther. 2009 Jul;8(13):1273-80.

9.

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D.

Blood. 2007 May 15;109(10):4441-9. Epub 2007 Jan 16.

10.

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.

Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M.

Cancer Lett. 2010 Dec 28;299(2):161-70. doi: 10.1016/j.canlet.2010.08.015. Epub 2010 Sep 17.

PMID:
20850924
11.

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.

Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.

Clin Cancer Res. 2011 Aug 1;17(15):5101-12. doi: 10.1158/1078-0432.CCR-10-3367. Epub 2011 Jun 28.

12.

Characterization of bortezomib-adapted I-45 mesothelioma cells.

Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR.

Mol Cancer. 2010 May 18;9:110. doi: 10.1186/1476-4598-9-110.

13.

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D.

Blood. 2006 Jan 1;107(1):257-64. Epub 2005 Sep 15.

14.

Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.

Ri M, Iida S, Ishida T, Ito A, Yano H, Inagaki A, Ding J, Kusumoto S, Komatsu H, Utsunomiya A, Ueda R.

Cancer Sci. 2009 Feb;100(2):341-8. doi: 10.1111/j.1349-7006.2008.01038.x.

15.

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.

Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D.

Blood. 2011 Jan 27;117(4):1270-9. doi: 10.1182/blood-2010-04-278853. Epub 2010 Nov 24.

16.

Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.

Babcock JT, Nguyen HB, He Y, Hendricks JW, Wek RC, Quilliam LA.

J Biol Chem. 2013 May 31;288(22):15687-98. doi: 10.1074/jbc.M112.431056. Epub 2013 Apr 23.

17.
18.

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K.

Blood. 2012 Jan 19;119(3):826-37. doi: 10.1182/blood-2011-07-366492. Epub 2011 Nov 29. Erratum in: Blood. 2014 Jul 24;124(4):663. De Bryune, Elke [corrected to De Bruyne, Elke].

19.

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA.

Clin Cancer Res. 2010 Jan 15;16(2):554-65. doi: 10.1158/1078-0432.CCR-09-1937. Epub 2010 Jan 12.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk